University of Washington Medical Center selects RayStation

The Department of Radiation Oncology at UW Medical Center has purchased RayStation®, which will become its primary clinical radiation therapy treatment planning system and research platform in 2017.

RayStation will be used for all external beam treatment planning at the University of Washington. The system will feature several advanced functionalities, including adaptive planning, deformable registration, fallback planning and the unique Plan Explorer tool.  Plan Explorer enables automatic generation of a large number of high-quality treatment plans for different treatment techniques and types of machines, based on selected clinical goals.

The university also plans to continue its internal development of neutron planning, utilizing the research and interface tools in RayStation.

Johan Löf, CEO of RaySearch Laboratories, says: “UW Medical Center is a cutting-edge cancer center. Its pioneering focus is a perfect match for RayStation, which supports the most advanced techniques and technologies across a variety of different machines. We are delighted to be a partner in advancing both treatment and research.”

About University of Washington, Department of Radiation Oncology
The University of Washington is recognized as one of the premier cancer centers in the US. The Department of Radiation Oncology offers a complete spectrum of radiation therapy options for a wide range of cancers, including extremely rare cancers. It provides the widest range of radiation therapy modalities. In addition to photon and electron radiation, it offers both neutron and proton particle therapies. A core value for the department is to bring an innovative, caring, comprehensive and collaborative approach to its three service areas: Clinical Care, Education, and Research.

About RayStation
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.

About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world and distributes products through licensing agreements with leading medical technology companies. The company is also developing the next-generation oncology information system, RayCare®*, which comprises a new product area for RaySearch, and which will be launched in 2017. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. The company was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the share has been listed on NASDAQ Stockholm since November 2003.

* Subject to regulatory clearance in some markets

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00
johan.lof@raysearchlabs.com

About Us

RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation® treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies such as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been launched via partners and RaySearch’s software is used by over 2,500 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institute in Stockholm and the company is listed in the Small Cap segment on Nasdaq Stockholm.

Subscribe

Media

Media

Documents & Links